Fig. 6: Identifying the reciprocal effect of stromal AR action on prostatic epithelial organoid oncogenic transformation and growth.

a Organoid culture of prostatic epithelial cells from 12-week-old Hi-Myc:R26^mTmG/+:Gli1^CreER/+ and Hi-Myc:R26^mTmG/+:Ar^L/Y:Gli1^CreER/+ mice, following treatment with vehicle, IGF1 (100 ng/ml), or IGF1 (100 ng/ml) + IGFBP3 (1 μg/ml). Representative of brightfield images and HE staining showing organoid morphology and structure observed in indicated groups. Scale bars, 400 μm and 25 μm. b Quantification of individual organoid size. Organoids (n = 100) per group examined over three independent experiments. The center line represents the median value in each group. c Quantification of organoid forming efficiency showing the percentage of organoids above 50 μm diameter per total cells seeded at day 0 in a well. The center line represents the median value, the box borders represent the lower and upper quartiles (25% and 75% percentiles, respectively) and the ends of the bottom and top whiskers represent the minimum and maximum values, respectively, for eight independent samples over three biological replicates. d Representative images of IHC staining with the indicated antibodies. Scale bars, 25 μm. e–f Organoid culture of prostatic epithelial cells from 12-week-old Hi-Myc:R26^mTmG/+:Gli1^CreER/+ and Hi-Myc:R26^mTmG/+:Ar^L/Y:Gli1^CreER/+ mice, following treatment with IGF1 (100 ng/ml), IGF1 (100 ng/ml) + ICG-001 (5 μM), or IGF1 (100 ng/ml) + iCRT3 (5 μM). Representative brightfield images and HE staining showing organoid morphology and structure observed in indicated groups. Scale bars, 400 μm and 25 μm. b, c Two-sided Student’s t-test for IGF1-treated groups versus IGF1 + IGFBP3-treated groups in HiMYC or HiMYC-ARKO, ^**p < 0.01. Source data and the exact p-values are provided in the “Source Data file”.